A selection of major announcements

1. Sinopec Oil Service: The wholly-owned subsidiary won the bid for 1,389 billion yuan of engineering projects, accounting for about 1.88% of the company's revenue in 2022

$SINOPEC SSC (01033.HK)$It was announced that Sinopec Petroleum Engineering Construction Co., Ltd., a wholly-owned subsidiary, won the bid for the Hulin-Changchun Gas Pipeline Project Construction General Contracting Section 2 of China Petroleum Pipeline Network Group Co., Ltd., with a bid amount of 1,389 billion yuan, accounting for about 1.88% of the company's 2022 revenue under Chinese accounting standards. The second section that the company won the bid for is 331.7 kilometers long. There are several construction projects such as stations, valve chambers, directional drilling, and crossing along the route. It is the longest section of the three bid sections.

2. Shenzhen Holdings: Total contract sales in January-November were 23.826 billion yuan, up 117.2% year on year

$SHENZHEN INVEST (00604.HK)$An announcement was issued. In November 2023, the Group's unaudited contract sales volume was approximately RMB 657 million, down 83.7% from the previous month and 42.5% from the same period last year. The contract sales area was about 26,200 square meters, down 74.5% from the previous month and 38.0% from the same period last year. From January to November 2023, the Group's unaudited total contract sales volume was approximately RMB 23.826 billion, up 117.2% from the same period last year.

3. Jianye Real Estate: January-November contract sales of 13.6 billion yuan, a year-on-year decrease of 37.6%

$CENTRAL CHINA (00832.HK)$It was announced that in November 2023, the Group obtained property contract sales of RMB 890 million, a year-on-year decrease of 18.1%; contract sales area of 105,200 square meters, a year-on-year decrease of 31.7%; and an average sales price of RMB 8,478 per square meter, an increase of 19.9% over the previous year. In the 11 months ended November 30, 2023, the Group has obtained total property contract sales of RMB 13.60 billion, a year-on-year decrease of 37.6%.

4. Yuanda Pharmaceutical: Affiliated with Doptel Pharmaceutical signed an equity investment agreement to acquire 27% of the latter's shares for no more than 190 million yuan

$GRANDPHARMA (00512.HK)$It was announced that the subsidiary Xi'an Beilin signed an investment agreement with Doptai Pharmaceutical. After the relevant conditions are met, Xi'an Beilin will acquire 27% of Doptai Pharmaceutical Technology's shares at a cost of no more than 190 million yuan. Doptai Pharmaceutical Technology is mainly engaged in the production and sale of the core products Maixukang capsules and Maixukang enteric tablets. This equity investment will open up in-depth strategic cooperation between the two sides and further strengthen the Group's market position in the field of cardiovascular and cerebrovascular disease treatment.

5. Luye Pharmaceutical: Innovative drug rubitidine approved for listing in Hong Kong, China

$LUYE PHARMA (02186.HK)$According to the announcement, ZEPZELCA (“rubitidine”) or (“LY01017"), a product introduced by the Group with permission from PharmaMar, S.A. (“Pharma Mar”), has been officially approved for marketing by the Pharmaceutical Industry and Poison Administration of the Hong Kong Special Administrative Region of China for the treatment of adult patients with metastatic small cell lung cancer (“SCLC”) who have progressed during or after chemotherapy with platinum drugs.

Investment and operation

$SINOPEC SSC (01033.HK)$: The wholly-owned subsidiary won the bid of 1,389 million yuan for the project, accounting for about 1.88% of the company's revenue in 2022

$SHENZHEN INVEST (00604.HK)$: From January to November, total contract sales of 23.826 billion yuan increased 117.2% year on year

$GREENLAND HK (00337.HK)$: January-November contract sales of 14.852 billion yuan increased 5.82% year-on-year

$CENTRAL CHINA (00832.HK)$: January-November contract sales of 13.60 billion yuan decreased by 37.6% year-on-year

$CH ENERGY ENG (03996.HK)$It is planned to invest in China Energy Construction and the 1 million kilowatt network load storage project

Pharmaceutical Innovation

$CARSGEN-B (02171.HK)$: Clinical trials suspended in the US due to CMC-related issues

$CMS (00867.HK)$: Lucotinib phosphate cream obtained approval notice for phase III vitiligo drug clinical trial in China

$LUYE PHARMA (02186.HK)$: Innovative drug rubitidine approved for listing in Hong Kong, China

$CSPC PHARMA (01093.HK)$: Dextromethorphan hydrobromide and quinidine sulphate tablets were approved for clinical trials

$SINO BIOPHARM (01177.HK)$: TQH2722 shows good safety and tolerability

$GRANDPHARMA (00512.HK)$: The subsidiary signed an equity investment agreement with Doptai Pharmaceutical to acquire 27% of the latter's shares for no more than 190 million yuan

Equity incentives

$WEIMOB INC (02013.HK)$A total of 5.816,400 restricted share units were granted

Increase or decrease holdings

$AIM VACCINE (06660.HK)$: Controlling shareholders have increased their H shares several times in a row

Repurchase cancellation

$TENCENT (00700.HK)$Repurchase of 1.3 million shares at a cost of HK$402 million on December 12

$HSBC HOLDINGS (00005.HK)$On December 11, 2,996,800 shares were repurchased at a cost of HK$180 million

$AIA (01299.HK)$Repurchase of 2.146 million shares at a cost of HK$135 million on December 12

$WUXI BIO (02269.HK)$On December 12, 3.25 million shares were repurchased at a cost of HK$92.747,700

$SUNSHINE PAPER (02002.HK)$Repurchase of 15.242 million shares at a cost of HK$47.574 million on December 12

$SINOPEC CORP (00386.HK)$On December 12, it spent HK$35.525,500 to repurchase 9.214,000 shares

$YUM CHINA (09987.HK)$On December 11, 75,200 shares were repurchased at a cost of 3 million US dollars

$COSCO SHIP HOLD (01919.HK)$Repurchase of 2,465,500 shares at a cost of HK$17.441,300 on December 12

$DONGFENG GROUP (00489.HK)$On December 12, 3.966 million shares were repurchased at a cost of HK$15.783,500

$ESR (01821.HK)$On December 12, 1.5 million shares were repurchased at a cost of HK$14.6 million

$BEKE-W (02423.HK)$On December 11, 396,000 shares were repurchased at a cost of 1.99 million US dollars

$SWIRE PACIFIC A (00019.HK)$On December 12, 170,000 shares were repurchased at a cost of HK$9.995,000